EUVIMEDObjevte EUVIMED
Open access · CC BY-NC-ND 4.0

Silencing of lncRNA HOTAIR Using Eyedrops as a Potential Treatment for Diabetes-Associated Retinal Dysregulation and Dysfunction

Eric Wang, Biao Feng, Shali Chen, Honglin Wang, Ting Ling, Subrata Chakrabarti

Investigative Ophthalmology & Visual Science · 2026

DOI: 10.1167/iovs.67.1.24 ↗

At a glance

Journal article in Investigative Ophthalmology & Visual Science, 2026. Written by Eric Wang and 5 co-authors. Institution: Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada. Major MEDLINE topics: Diabetic Retinopathy, RNA, Long Noncoding, RNA, Small Interfering, Gene Silencing. Cited 2 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Purpose

Diabetic retinopathy (DR), a major cause of blindness in working-age adults, is driven by vascular dysfunction mediated by various angiogenic regulators. Although anti-VEGF therapies reduce vision impairment in some patients, they have limitations that leave room for novel treatments. The long non-coding RNA (lncRNA) HOX transcript antisense intergenic RNA (HOTAIR), which is upregulated in the retina in diabetes and regulates a range of factors including VEGF, contributes to DR pathology. Silencing HOTAIR prevents the dysregulation of VEGF and other factors. We explored targeting HOTAIR using siRNA conjugated to n-acetylgalactosamine (GalNAc) moieties for retinal delivery as a means of preventing diabetes-associated pathology in the retina.

Methods

GalNAc-modified siHOTAIR was evaluated in human retinal endothelial cells in vitro and using various models in vivo. The effects of GalNAc-modified siHOTAIR were assessed on the RNA, protein, and functional levels.

Results

GalNAc-modified siHOTAIR effectively entered retinal endothelial cells in vitro, and inhibited glucose-induced endothelial dysfunction by blocking multiple factors, including VEGF-A. GalNAc-siRNA localized to the retina in vivo following topical delivery, and prevented diabetes-induced pathological retinal changes with efficacy comparable to intravitreal injection.

Conclusions

GalNAc-modified siHOTAIR thus represents a potential therapeutic strategy that not only inhibits VEGF but also targets other pathogenic mediators regulated by HOTAIR, potentially offering broader efficacy than anti-VEGF monotherapy. Furthermore, it achieves this via noninvasive, topical delivery, circumventing the need for intravitreal injections required by current treatments. Thus, with further development, GalNAc-modified siHOTAIR may become an overall better approach to treating DR.

Subjects

MeSH terms (MEDLINE)

Diabetic RetinopathyRNA, Long NoncodingRNA, Small InterferingGene SilencingGene Expression RegulationAnimalsHumansVascular Endothelial Growth Factor AOphthalmic SolutionsCells, CulturedDiabetes Mellitus, ExperimentalMiceBlotting, WesternEndothelial CellsMice, Inbred C57BLMale

Substances

RNA, Long NoncodingRNA, Small InterferingVascular Endothelial Growth Factor AOphthalmic SolutionsHOTAIR long untranslated RNA, human

Authors and institutions

  • Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.
  • i-RNA Corporation, London, Ontario, Canada.

Cite

APA

Wang, E., Feng, B., Chen, S., Wang, H., Ling, T., & Chakrabarti, S. (2026). Silencing of lncRNA HOTAIR Using Eyedrops as a Potential Treatment for Diabetes-Associated Retinal Dysregulation and Dysfunction. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.1.24

Vancouver

Wang E, Feng B, Chen S, Wang H, Ling T, Chakrabarti S. Silencing of lncRNA HOTAIR Using Eyedrops as a Potential Treatment for Diabetes-Associated Retinal Dysregulation and Dysfunction. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.1.24

BibTeX
@article{Wang2026,
  author = {Wang, Eric and Feng, Biao and Chen, Shali and Wang, Honglin and Ling, Ting and Chakrabarti, Subrata},
  title = {Silencing of lncRNA HOTAIR Using Eyedrops as a Potential Treatment for Diabetes-Associated Retinal Dysregulation and Dysfunction},
  journal = {Investigative Ophthalmology & Visual Science},
  year = {2026},
  doi = {10.1167/iovs.67.1.24}
}
Start for free →